Ghassan Kamel, MD
Pulmonary Disease · Saint Louis, MONPI 1700174638
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Sanofi at 42.6% of the total. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $493.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$12K
- AstraZeneca$8K
- Genentech USA, Inc.$8K
- Inari Medical, Inc.$343
- GSK$137
- Sanofi-aventis U.S. LLC$100
- plus $215 from 5 others
What the payments were for
- Consulting fees$16,59359%
- Speaking & faculty fees$7,25026%
- Travel & lodging$9623%
- Food & beverage$3,13511%
- Education$2131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 25 | $11,982 |
| AstraZeneca | 11 | $7,838 |
| Genentech USA, Inc. | 9 | $7,538 |
| Inari Medical, Inc. | 2 | $343 |
| GSK | 4 | $137 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Abiomed | 1 | $100 |
| Abbott | 1 | $65 |
| Regeneron | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$11,355
- TEZSPIRE$7,622
- XOLAIR$1,780
- FLOWTRIEVER CATHETER, S$343
- CT THROMBECTOMY SYSTEM KIT$343
- NUCALA$101
How this compares
$28,152 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,049 |
| Spiriva RespimatTiotropium Bromide | 27 | $14,043 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,948 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $7,834 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,994 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $6,330 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,181 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 126 | $3,013 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,714 |
| Ventolin HfaAlbuterol Sulfate | 15 | $829 |
| Azelastine Hcl | 11 | $347 |
| Fluticasone Propionate | 19 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $137 | $44,67479 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $7,838 | $13,32438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.